PCT/EP2012/067815
The method for prognosis of a patient suffering from diffuse large B-cell lymphoma (DLBCL) comprises determining in a sample from said patient the level of at least one biomarker selected from the group consisting of VEGF, BCL6, CD68, CD20, and combinations thereof.
PCT/EP2012/067815
The method for prognosis of a patient suffering from diffuse large B-cell lymphoma (DLBCL) comprises determining in a sample from said patient the level of at least one biomarker selected from the group consisting of VEGF, BCL6, CD68, CD20, and combinations thereof.
PCT/EP2012/067815
O método para prognóstico de um paciente que sofra de linfoma difuso de grandes celulas B (DLBCL) compreende a determinação numa amostra do referido paciente do nível de, pelo menos, um biomarcador selecionado do grupo constituído por VEGF, BCL6, CD68, CD20, e as suas combinações.
PCT/EP2010/069058
The invention relates to methods of predicting the clinical outcome of brain cancer patients based on the LOH levels of the PTEN gene and on the expression levels or the polysomy / amplification levels of EGFR gene in a sample from said patients.
PCT/EP2010/069058
The invention relates to methods of predicting the clinical outcome of brain cancer patients based on the LOH levels of the PTEN gene and on the expression levels or the polysomy / amplification levels of EGFR gene in a sample from said patients.
PCT/EP2010/069058
A invenção está relacionada com métodos de previsão dos resultados clínicos de pacientes com tumores cerebrais com base nos níveis de LOH do gene PTEN e na expressão dos níveis ou nos níveis de polissomia/amplificação do gene EGFR numa amostra dos pacientes referidos.
EP14382545.3
EP14382545.3
EP14382545.3
Do you want to get in touch with the R+D department?
Tell us how we can help you